<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-04-14T13:46:48Z</responseDate><request verb="GetRecord" identifier="oai:uvadoc.uva.es:10324/61877" metadataPrefix="mods">https://uvadoc.uva.es/oai/request</request><GetRecord><record><header><identifier>oai:uvadoc.uva.es:10324/61877</identifier><datestamp>2024-12-16T07:27:16Z</datestamp><setSpec>com_10324_1133</setSpec><setSpec>com_10324_931</setSpec><setSpec>com_10324_894</setSpec><setSpec>col_10324_1209</setSpec></header><metadata><mods:mods xmlns:mods="http://www.loc.gov/mods/v3" xmlns:doc="http://www.lyncode.com/xoai" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-1.xsd">
<mods:name>
<mods:namePart>Gutiérrez Abejón, Eduardo</mods:namePart>
</mods:name>
<mods:name>
<mods:namePart>Herrera Gómez, Francisco Magno</mods:namePart>
</mods:name>
<mods:name>
<mods:namePart>Pedrosa Naudín, M. Aránzazu</mods:namePart>
</mods:name>
<mods:name>
<mods:namePart>Tamayo Gómez, Eduardo</mods:namePart>
</mods:name>
<mods:name>
<mods:namePart>Álvarez González, Francisco Javier</mods:namePart>
</mods:name>
<mods:extension>
<mods:dateAvailable encoding="iso8601">2023-10-04T11:10:25Z</mods:dateAvailable>
</mods:extension>
<mods:extension>
<mods:dateAccessioned encoding="iso8601">2023-10-04T11:10:25Z</mods:dateAccessioned>
</mods:extension>
<mods:originInfo>
<mods:dateIssued encoding="iso8601">2022</mods:dateIssued>
</mods:originInfo>
<mods:identifier type="citation">Medicina, 2022, Vol. 58, Nº. 6, 829</mods:identifier>
<mods:identifier type="issn">1648-9144</mods:identifier>
<mods:identifier type="uri">https://uvadoc.uva.es/handle/10324/61877</mods:identifier>
<mods:identifier type="doi">10.3390/medicina58060829</mods:identifier>
<mods:identifier type="publicationfirstpage">829</mods:identifier>
<mods:identifier type="publicationissue">6</mods:identifier>
<mods:identifier type="publicationtitle">Medicina</mods:identifier>
<mods:identifier type="publicationvolume">58</mods:identifier>
<mods:identifier type="essn">1648-9144</mods:identifier>
<mods:abstract>Background and Objectives: One of the most serious clinical outcomes in hospitalized patients with COVID-19 is severe acute respiratory syndrome (SARS). The aim is to analyze pharmacological treatment, survival and the main mortality predictors. Materials and Methods: A real-world data study from COVID-19-hospitalized patients with SARS from 1 March to 31 May 2020 has been carried out. Variables such as hospital length of stay, ventilation type and clinical outcomes have been taken into account. Results: In Castile and Leon, 14.03% of the 7307 in-hospital COVID-19 patients developed SARS, with a mortality rate of 42.53%. SARS prevalence was doubled in males compared to females, and 78.54% had an age of 65 years or more. The most commonly used medicines were antibiotics (89.27%), antimalarials (68.1%) and corticosteroids (55.9%). Survival of patients developing SARS was lower compared to patients without this complication (12 vs. 13 days). The main death predictors were disseminated intravascular coagulation (DIC) (OR: 13.87) and age (>65 years) (OR: 7.35). Conclusions: Patients older than 65 years who develop DIC have a higher probability of hospital death. Tocilizumab and steroids have been linked to a lower incidence of hospital death, being the main treatment for COVID-19 hospitalized patients with SARS.</mods:abstract>
<mods:language>
<mods:languageTerm>eng</mods:languageTerm>
</mods:language>
<mods:accessCondition type="useAndReproduction">info:eu-repo/semantics/openAccess</mods:accessCondition>
<mods:accessCondition type="useAndReproduction">http://creativecommons.org/licenses/by/4.0/</mods:accessCondition>
<mods:accessCondition type="useAndReproduction">© 2022 The Authors</mods:accessCondition>
<mods:accessCondition type="useAndReproduction">Atribución 4.0 Internacional</mods:accessCondition>
<mods:subject>
<mods:topic>SARS-CoV-2</mods:topic>
</mods:subject>
<mods:subject>
<mods:topic>COVID-19</mods:topic>
</mods:subject>
<mods:subject>
<mods:topic>SARS (Disease)</mods:topic>
</mods:subject>
<mods:subject>
<mods:topic>Syndromes</mods:topic>
</mods:subject>
<mods:subject>
<mods:topic>Clinical findings</mods:topic>
</mods:subject>
<mods:subject>
<mods:topic>Pharmacotherapy</mods:topic>
</mods:subject>
<mods:subject>
<mods:topic>Survival</mods:topic>
</mods:subject>
<mods:subject>
<mods:topic>Supervivencia</mods:topic>
</mods:subject>
<mods:subject>
<mods:topic>Virology</mods:topic>
</mods:subject>
<mods:titleInfo>
<mods:title>Hospitalized COVID-19 patients with severe acute respiratory syndrome: A population-based registry analysis to assess clinical findings, pharmacological treatment and survival</mods:title>
</mods:titleInfo>
<mods:genre>info:eu-repo/semantics/article</mods:genre>
</mods:mods></metadata></record></GetRecord></OAI-PMH>